Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

BRIDGEWATER, N.J.–(BUSINESS WIRE)– Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan® and…

Occlutech starts patient dosing in the FROST study to look into using an atrial flow regulator to treat heart failure with preserved ejection fraction (HFpEF).

One of the top manufacturers of minimally invasive structural heart disease devices, Occlutech Holding AG (Occlutech), has announced the enrollment of the first patient in the FROST-HF study. In the FROST-HF study, patients with heart failure with either preserved ejection…

Registration Form


This will close in 0 seconds

WhatsApp Telegram